Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neus Villamor

Showing results (91-100 of 136) with videos related to

Pageof 14
Sort By:
Diagnostic Pathology|April 30, 2025
CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated casesLaura González-Guerrero, Helena Castellet, Clara Martínez, et al.
Oncotarget|June 10, 2015
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profileLourdes Martín-Martín, Antonio López, Belén Vidriales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradicationFrancesc Bosch, Ana Ferrer, Neus Villamor, et al.
International Journal of Cancer|November 24, 2018
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemiaEriong Lee-Vergés, Bola S Hanna, Haniyeh Yazdanparast, et al.
Cells|November 27, 2024
Association of Genomic Alterations with the Presence of Serum Monoclonal Proteins in Chronic Lymphocytic LeukemiaJuan A Piñeyroa, Irene López-Oreja, Ferran Nadeu, et al.
British Journal of Haematology|December 6, 2018
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab eraAlfredo Rivas-Delgado, Laura Magnano, Miriam Moreno-Velázquez, et al.
Hematological Oncology|May 25, 2022
Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemiaJuan A Piñeyroa, Laura Magnano, Andrea Rivero, et al.
The American Journal of Surgical Pathology|October 2, 2015
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive DiseaseDaniel Martinez, Alba Navarro, Alejandra Martinez-Trillos, et al.
Blood|September 6, 2018
Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemiaGabriel Bretones, Miguel G Álvarez, Javier R Arango, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaFrancesc Bosch, Pau Abrisqueta, Neus Villamor, et al.
Pageof 14

Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
Diagnostic Pathology|April 30, 2025
CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated casesLaura González-Guerrero, Helena Castellet, Clara Martínez, et al.
Oncotarget|June 10, 2015
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profileLourdes Martín-Martín, Antonio López, Belén Vidriales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradicationFrancesc Bosch, Ana Ferrer, Neus Villamor, et al.
International Journal of Cancer|November 24, 2018
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemiaEriong Lee-Vergés, Bola S Hanna, Haniyeh Yazdanparast, et al.
Cells|November 27, 2024
Association of Genomic Alterations with the Presence of Serum Monoclonal Proteins in Chronic Lymphocytic LeukemiaJuan A Piñeyroa, Irene López-Oreja, Ferran Nadeu, et al.
British Journal of Haematology|December 6, 2018
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab eraAlfredo Rivas-Delgado, Laura Magnano, Miriam Moreno-Velázquez, et al.
Hematological Oncology|May 25, 2022
Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemiaJuan A Piñeyroa, Laura Magnano, Andrea Rivero, et al.
The American Journal of Surgical Pathology|October 2, 2015
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive DiseaseDaniel Martinez, Alba Navarro, Alejandra Martinez-Trillos, et al.
Blood|September 6, 2018
Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemiaGabriel Bretones, Miguel G Álvarez, Javier R Arango, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaFrancesc Bosch, Pau Abrisqueta, Neus Villamor, et al.
Pageof 14